Sellas Life Sciences Group (US:SLS) — Company Overview, News & Financial Data
Sellas Life Sciences is a biopharmaceutical company developing novel cancer immunotherapies targeting hematologic cancers.
Sellas Life Sciences Group
Sellas Life Sciences (NASDAQ:SLS) is a biopharmaceutical company focused on the development of novel cancer immunotherapies. Its primary projects revolve around advancing treatments that target hematologic cancers and solid tumors, utilizing proprietary technology platforms to develop its pipeline. One of Sellas's flagship products includes GPS, a therapeutic vaccine aimed at multiple cancer types, demonstrating potential in improving patient outcomes by stimulating the immune system to attack cancer cells. The company's objective is to continue groundbreaking research and clinical trials to bring innovative therapies to market, offering new hope and options for patients battling cancer. With a commitment to exploiting the full potential of its technologies, Sellas is dedicated to making significant strides in oncology.
Snapshot
Operations
Products and/or services of Sellas Life Sciences Group
- GPS, a cancer immunotherapy targeting WT1-expressing cancers, representing a broad range of hematologic malignancies and solid tumors.
- Nelipepimut-S, targeting HER2 3+ expressing breast cancer in combination with trastuzumab for a more effective treatment option.
- A multifaceted clinical research program focusing on advanced melanoma treatments, exploring the efficacy and safety of novel immunotherapeutics.
- Collaboration with leading pharmaceutical companies for the development of next-generation cancer vaccines aimed at multiple tumor antigens.
- Investment in proprietary biotechnological platforms to enhance the precision and delivery of immunotherapies for hard-to-treat cancers.
- Engagement in a partnership to explore the potential of mRNA technology for creating personalized cancer vaccines targeting specific mutations.
Sellas Life Sciences Group executive team
- Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, President, CEO & Director
- Mr. John Thomas Burns CPASenior VP & CFO
- Dr. Dragan Cicic M.D., MBASenior VP & Chief Development Officer
- Ms. Stacy E. YeungVP, General Counsel & Corporate Secretary
- Mr. Andrew ElnatanSenior VP of Regulatory Affairs, CMC & Quality